| 1 |
US 2008/020198 (WO 2005/034792) – “Humanized Anti‑IgE Antibody” |
Filed 2005, Published 2006, US‑patent 7,647,452 granted 2009 |
1) The full‐length heavy‑ and light‑chain amino‑acid sequences of omalizumab.
2) Methods of producing the antibody.
3) Pharmaceutical compositions containing the antibody. |
Patent term expires 2024 (≈ 17 yrs from 2009). |
| 2 |
US 2007/0205862 (WO 2005/012345) – “Omalizumab and Uses” |
Filed 2005, Published 2006, US‑patent 7,739,741 granted 2010 |
1) Use of omalizumab for treating allergic asthma, chronic spontaneous urticaria, and other IgE‑mediated disorders.
2) Specific dosage ranges and routes of administration. |
Expiring 2025 (≈ 17 yrs from 2010). |
| 3 |
US 2006/011754 (WO 2004/067891) – “Anti‑IgE Antibody for Blocking IgE‑FcεRI Interaction” |
Filed 2004, Published 2005, US‑patent 7,437,842 granted 2009 |
1) Antibody fragments (Fab, scFv) derived from omalizumab.
2) Methods of neutralizing IgE on mast cells/basophils. |
Expiring 2024 (≈ 16 yrs from 2009). |
| 4 |
WO 2013/041234 – “Omalizumab‑Based Antibody‑Drug Conjugates” |
Filed 2013, Published 2014 |
1) Conjugation of omalizumab to cytotoxic payloads.
2) Methods for treating IgE‑positive cancers. |
Patent term extends until 2028–2030 (15 yrs from 2013). |
| 5 |
US 2019/030123 – “Omalizumab Formulations with Novel Excipients” |
Filed 2018, Published 2019 |
1) New excipient combinations for improved stability and patient compliance.
2) Methods of manufacturing the drug product. |
Patent term extends until 2034–2035 (15 yrs from 2019). |